Strength Seen in Catalyst (CPRX): Can Its 6.7% Jump Turn into More Strength?
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·7h ago
More News
Catalyst Pharmaceuticals (NASDAQ:CPRX) Sets New 1-Year High - Here's What Happened
Catalyst Pharmaceuticals (NASDAQ:CPRX) Reaches New 52-Week High - What's Next...
MarketBeat·20h ago
SNY & REGN's Dupixent Wins FDA Nod for Pediatric Use in Urticaria
Sanofi wins FDA nod to expand Dupixent in kids aged 2-11 years, marking the first biologic for young patients with uncontrolled CSU.
Zacks·22h ago
SNY's Tzield Gets FDA Nod for Kids, Sarclisa SC BLA Faces Delay
Sanofi wins FDA nod to expand Tzield's use to younger patients, while Sarclisa SC review faces delay with a new decision date set for July 2026.
Zacks·22h ago
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
Inhibrx Biosciences stock surges after phase I/II CRC data of ozekibart show strong response rates and durable benefit, alongside a new FDA filing for ozekibart in chondrosarcoma.
Amneal's deal to buy Kashiv for up to $1.10B aids biosimilar push. The company posts strong preliminary Q1 results and raises 2026 EPS guidance.
Zacks·1d ago
European Commission Approves MRNA's COVID-19-Influenza Combo Shot
Moderna wins EU approval for its COVID-19-flu combo shot mCombriax, backed by strong phase III data showing superior immune response vs standalone vaccines.
Zacks·2d ago
NVO's Etavopivat Hits Key Goals in Phase III Sickle Cell Disease Study
Novo Nordisk's etavopivat meets phase III goals, cutting VOCs and boosting haemoglobin in sickle cell disease, with data backing a favorable safety profile.
Zacks·3d ago
LLY to Buy Oncology Biotech Kelonia Therapeutics for $7 Billion
Eli Lilly is set to acquire Kelonia Therapeutics in a $7B deal, boosting its genetic medicine platform with a novel in vivo CAR-T therapy for cancer.
Zacks·3d ago
Agios Stock Sinks 23% as NVO's PKR Activator Meets Goal in SCD Study
AGIO shares plunge after Novo Nordisk's strong sickle cell data raised doubts about mitapivat's competitiveness and approval prospects.